<p>摩根士丹利的投资分析师在周五发布的一份报告中将阿卡迪亚制药（NASDAQ:ACAD）的目标股价从 30.00 美元下调至 28.00 美元。该公司目前对这家生物制药公司的股票给予&#34;超配&#34;评级。摩根士丹利的价格目标表明，相较于公司当前股价，有 57.84% 的潜在上涨空间。</p>
<p>获取 <strong>阿卡迪亚制药</strong> 的警报：</p>
<ul>
<li>阿卡迪亚制药：中型生物科技公司正在发生重大变化</li>
</ul>
<p>ACAD 已成为其他几份研究报告的主题。Oppenheimer 重申了&#34;市场表现&#34;评级，并在 5 月 6 日的报告中对阿卡迪亚制药的股票设定了 19.00 美元的价格目标。加拿大皇家银行重申了&#34;表现优异&#34;评级，并在 6 月 25 日的报告中将阿卡迪亚制药的股票目标价设定为 29.00 美元。Robert W. Baird 将阿卡迪亚制药的目标股价从 31.00 美元下调至 28.00 美元，并为该公司设定了&#34;表现优异&#34;评级。Mizuho 将阿卡迪亚制药的目标股价从 25.00 美元下调至 21.00 美元，并为该公司设定了&#34;中性&#34;评级。最后，摩根大通将阿卡迪亚制药的目标股价从 29.00 美元下调至 25.00 美元，并为该公司设定了&#34;超配&#34;评级。四位股票研究分析师对该股票给予持有评级，十三位给予买入评级，一位给予强烈买入评级。根据 MarketBeat.com 的数据，该股目前的共识评级为&#34;中等买入&#34;，平均目标股价为 28.59 美元。</p>
<p><strong>查看我们对阿卡迪亚的最新研究报告</strong></p>
<h2>阿卡迪亚制药股价表现</h2>
<p>周五午盘交易中，ACAD 股价上涨 0.09 美元，达到 17.74 美元。该股交易量为 700,451 股，相比平均交易量 1,724,612 股有所下降。该公司的市值为 29.3 亿美元，市盈率为-1,772.23，β系数为 0.38。该公司的 50 天简单移动平均线为 15.58 美元，200 天简单移动平均线为 20.60 美元。阿卡迪亚制药的 52 周最低价为 14.55 美元，最高价为 33.99 美元。</p>
<p>阿卡迪亚制药（NASDAQ:ACAD）于 5 月 8 日公布了其季度财报。这家生物制药公司报告称，该季度每股收益为 0.10 美元，超过了每股 0.04 美元的共识预期 0.06 美元。该季度公司营收为 2.0583 亿美元，低于分析师预期的 2.0831 亿美元。阿卡迪亚制药的净资产回报率为-0.41%，净利润率为-0.21%。与去年同期相比，阿卡迪亚制药的营收增长了 73.8%。去年同期，该公司每股收益为（0.27）美元。分析师预计，阿卡迪亚制药本财年的每股收益将为 0.58 美元。</p>
<h2>内部交易活动</h2>
<p>另外，首席执行官 Stephen Davis 于 5 月 2 日星期四以每股 16.94 美元的均价出售了 11,427 股阿卡迪亚制药股票。交易完成后，首席执行官在公司中直接持有 155,231 股股票，价值 2,629,613.14 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此链接访问。此外，首席财务官 Mark C. Schneyer 于 5 月 2 日星期四以每股 16.94 美元的均价出售了 3,503 股公司股票。交易总价值为 59,340.82 美元。交易完成后，首席财务官现在持有公司股票 32,053 股，价值 542,977.82 美元。该交易已在提交给证券交易委员会的法律文件中披露，可通过此链接访问。此外，首席执行官 Stephen Davis 于 5 月 2 日星期四以每股 16.94 美元的均价出售了 11,427 股公司股票。交易总价值为 193,573.38 美元。交易完成后，首席执行官在公司中直接持有 155,231 股股票，价值约 2,629,613.14 美元。有关此次交易的披露可在此处找到。过去 90 天，内部人士共出售 20,708 股公司股票，价值 348,697 美元。公司内部人士持有公司股份的比例为 28.30%。</p>
<h2>阿卡迪亚制药的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近调整了他们对该股票的持股。Empire Life Investments Inc. 在第四季度增加了对 ACADIA Pharmaceuticals 股份的持股比例，增长了 0.3%。Empire Life Investments Inc. 现在拥有 174,815 股这家生物制药公司的股票，价值$5,473,000，上季度购买了额外的 467 股。Handelsbanken Fonder AB 在第四季度增加了对 ACADIA Pharmaceuticals 股份的持股比例，增长了 2.3%。Handelsbanken Fonder AB 现在拥有 31,633 股这家生物制药公司的股票，价值$990,000，上季度购买了额外的 700 股。瑞士国家银行在第一季度增加了对 ACADIA Pharmaceuticals 股份的持股比例，增长了 0.4%。瑞士国家银行现在拥有 210,604 股这家生物制药公司的股票，价值$3,894,000，上季度购买了额外的 800 股。Franklin Resources Inc. 在第四季度增加了对 ACADIA Pharmaceuticals 股份的持股比例，增长了 1.6%。Franklin Resources Inc. 现在拥有 50,405 股这家生物制药公司的股票，价值$1,578,000，上季度购买了额外的 803 股。最后，Covestor Ltd 在第一季度增加了对 ACADIA Pharmaceuticals 股份的持股比例，增长了 70.5%。Covestor Ltd 现在拥有 2,032 股这家生物制药公司的股票，价值$38,000，上季度购买了额外的 840 股。机构投资者持有该公司股份的 96.71%。</p>
<h2>关于 ACADIA Pharmaceuticals（获取免费报告）</h2>
<p>ACADIA Pharmaceuticals Inc. 是一家生物制药公司，专注于开发和商业化解决美国中枢神经系统（CNS）疾病和罕见疾病未满足医疗需求的创新药物。该公司提供 NUPLAZID（pimavanserin）用于治疗帕金森病精神病的幻觉和妄想；以及 DAYBUE，一种胰岛素样生长因子 1 氨基末端三肽的新型合成类似物，用于治疗雷特综合征。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们比 ACADIA Pharmaceuticals 更喜欢的股票</li>
<li>现在购买的 3 家最佳金融科技股</li>
<li>前三家饮料股：夏季收益揭示关键趋势</li>
<li>股息王子宝洁在盈利下滑后值得购买</li>
<li>这家金融股的盈利信号表明购买机会</li>
<li>什么是热门股票？热门股票解析</li>
<li>社交平台股价创新高：未来还有更多增长吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNBRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNBRA"/></p>
<p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和来自市场预测的金融数据生成的，以便为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 奥巴马的民主党全国委员会政变（来自 Stansberry Research）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjQ2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjQ2"/></p>
<h2>您现在是否应该投资$1,000 在 ACADIA Pharmaceuticals？</h2>
<p>在您考虑 ACADIA Pharmaceuticals 之前，您会想听到这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户在更广泛市场注意之前现在购买的股票... 而 ACADIA Pharmaceuticals 不在这个名单上。</p>
<p>尽管 ACADIA Pharmaceuticals 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

阿卡迪亚

<p>阿卡迪亚制药的目标股价由摩根大通从 30.00 美元下调至 28.00 美元，并给予该股票 “增持” 评级。其他几份研究报告也已发布关于阿卡迪亚制药。公司股票目前有一个 “中等买入” 的共识评级，平均目标股价为 28.59 美元。阿卡迪亚制药的股票交易价格为 17.74 美元，潜在上涨空间为 57.84%</p>

<p>ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) had its target price cut by investment analysts at Morgan Stanley from $30.00 to $28.00 in a report issued on Friday, Benzinga reports. The firm currently has an &#34;overweight&#34; rating on the biopharmaceutical company's stock. Morgan Stanley's price objective indicates a potential upside of 57.84% from the company's current price.</p>
<div class="lb-trans"><p>摩根士丹利的投资分析师在周五发布的一份报告中将阿卡迪亚制药（NASDAQ:ACAD）的目标股价从 30.00 美元下调至 28.00 美元。该公司目前对这家生物制药公司的股票给予&#34;超配&#34;评级。摩根士丹利的价格目标表明，相较于公司当前股价，有 57.84% 的潜在上涨空间。</p>
</div><p>Get <strong>ACADIA Pharmaceuticals</strong> alerts:</p>
<ul>
<li>Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves</li>
</ul>
<div class="lb-trans"><p>获取 <strong>阿卡迪亚制药</strong> 的警报：</p>
<ul>
<li>阿卡迪亚制药：中型生物科技公司正在发生重大变化</li>
</ul>
</div><p>ACAD has been the subject of several other research reports. Oppenheimer restated a &#34;market perform&#34; rating and issued a $19.00 price objective on shares of ACADIA Pharmaceuticals in a report on Monday, May 6th. Royal Bank of Canada reiterated an &#34;outperform&#34; rating and set a $29.00 price target on shares of ACADIA Pharmaceuticals in a report on Tuesday, June 25th. Robert W. Baird reduced their price target on ACADIA Pharmaceuticals from $31.00 to $28.00 and set an &#34;outperform&#34; rating for the company in a report on Thursday, May 9th. Mizuho reduced their price target on ACADIA Pharmaceuticals from $25.00 to $21.00 and set a &#34;neutral&#34; rating for the company in a report on Thursday, May 9th. Finally, JPMorgan Chase &amp; Co. reduced their price target on ACADIA Pharmaceuticals from $29.00 to $25.00 and set an &#34;overweight&#34; rating for the company in a report on Monday, March 25th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $28.59.</p>
<div class="lb-trans"><p>ACAD 已成为其他几份研究报告的主题。Oppenheimer 重申了&#34;市场表现&#34;评级，并在 5 月 6 日的报告中对阿卡迪亚制药的股票设定了 19.00 美元的价格目标。加拿大皇家银行重申了&#34;表现优异&#34;评级，并在 6 月 25 日的报告中将阿卡迪亚制药的股票目标价设定为 29.00 美元。Robert W. Baird 将阿卡迪亚制药的目标股价从 31.00 美元下调至 28.00 美元，并为该公司设定了&#34;表现优异&#34;评级。Mizuho 将阿卡迪亚制药的目标股价从 25.00 美元下调至 21.00 美元，并为该公司设定了&#34;中性&#34;评级。最后，摩根大通将阿卡迪亚制药的目标股价从 29.00 美元下调至 25.00 美元，并为该公司设定了&#34;超配&#34;评级。四位股票研究分析师对该股票给予持有评级，十三位给予买入评级，一位给予强烈买入评级。根据 MarketBeat.com 的数据，该股目前的共识评级为&#34;中等买入&#34;，平均目标股价为 28.59 美元。</p>
</div><p><strong>View Our Latest Research Report on ACAD</strong></p>
<div class="lb-trans"><p><strong>查看我们对阿卡迪亚的最新研究报告</strong></p>
</div><h2>ACADIA Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>阿卡迪亚制药股价表现</h2>
</div><p>Shares of ACAD traded up $0.09 during midday trading on Friday, hitting $17.74. The stock had a trading volume of 700,451 shares, compared to its average volume of 1,724,612. The firm has a market cap of $2.93 billion, a price-to-earnings ratio of -1,772.23 and a beta of 0.38. The company has a 50 day simple moving average of $15.58 and a two-hundred day simple moving average of $20.60. ACADIA Pharmaceuticals has a twelve month low of $14.55 and a twelve month high of $33.99.</p>
<div class="lb-trans"><p>周五午盘交易中，ACAD 股价上涨 0.09 美元，达到 17.74 美元。该股交易量为 700,451 股，相比平均交易量 1,724,612 股有所下降。该公司的市值为 29.3 亿美元，市盈率为-1,772.23，β系数为 0.38。该公司的 50 天简单移动平均线为 15.58 美元，200 天简单移动平均线为 20.60 美元。阿卡迪亚制药的 52 周最低价为 14.55 美元，最高价为 33.99 美元。</p>
</div><p>ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.06. The company had revenue of $205.83 million during the quarter, compared to analysts' expectations of $208.31 million. ACADIA Pharmaceuticals had a negative return on equity of 0.41% and a negative net margin of 0.21%. ACADIA Pharmaceuticals's revenue for the quarter was up 73.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.27) EPS. Analysts forecast that ACADIA Pharmaceuticals will post 0.58 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>阿卡迪亚制药（NASDAQ:ACAD）于 5 月 8 日公布了其季度财报。这家生物制药公司报告称，该季度每股收益为 0.10 美元，超过了每股 0.04 美元的共识预期 0.06 美元。该季度公司营收为 2.0583 亿美元，低于分析师预期的 2.0831 亿美元。阿卡迪亚制药的净资产回报率为-0.41%，净利润率为-0.21%。与去年同期相比，阿卡迪亚制药的营收增长了 73.8%。去年同期，该公司每股收益为（0.27）美元。分析师预计，阿卡迪亚制药本财年的每股收益将为 0.58 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, CEO Stephen Davis sold 11,427 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $16.94, for a total value of $193,573.38. Following the completion of the sale, the chief executive officer now directly owns 155,231 shares in the company, valued at $2,629,613.14. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other ACADIA Pharmaceuticals news, CFO Mark C. Schneyer sold 3,503 shares of the business's stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $16.94, for a total transaction of $59,340.82. Following the sale, the chief financial officer now owns 32,053 shares of the company's stock, valued at $542,977.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Stephen Davis sold 11,427 shares of the business's stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $16.94, for a total transaction of $193,573.38. Following the sale, the chief executive officer now directly owns 155,231 shares in the company, valued at approximately $2,629,613.14. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 20,708 shares of company stock worth $348,697. Corporate insiders own 28.30% of the company's stock.</p>
<div class="lb-trans"><p>另外，首席执行官 Stephen Davis 于 5 月 2 日星期四以每股 16.94 美元的均价出售了 11,427 股阿卡迪亚制药股票。交易完成后，首席执行官在公司中直接持有 155,231 股股票，价值 2,629,613.14 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此链接访问。此外，首席财务官 Mark C. Schneyer 于 5 月 2 日星期四以每股 16.94 美元的均价出售了 3,503 股公司股票。交易总价值为 59,340.82 美元。交易完成后，首席财务官现在持有公司股票 32,053 股，价值 542,977.82 美元。该交易已在提交给证券交易委员会的法律文件中披露，可通过此链接访问。此外，首席执行官 Stephen Davis 于 5 月 2 日星期四以每股 16.94 美元的均价出售了 11,427 股公司股票。交易总价值为 193,573.38 美元。交易完成后，首席执行官在公司中直接持有 155,231 股股票，价值约 2,629,613.14 美元。有关此次交易的披露可在此处找到。过去 90 天，内部人士共出售 20,708 股公司股票，价值 348,697 美元。公司内部人士持有公司股份的比例为 28.30%。</p>
</div><h2>Institutional Trading of ACADIA Pharmaceuticals</h2>
<div class="lb-trans"><h2>阿卡迪亚制药的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Empire Life Investments Inc. grew its stake in shares of ACADIA Pharmaceuticals by 0.3% during the fourth quarter. Empire Life Investments Inc. now owns 174,815 shares of the biopharmaceutical company's stock worth $5,473,000 after buying an additional 467 shares during the last quarter. Handelsbanken Fonder AB grew its stake in shares of ACADIA Pharmaceuticals by 2.3% in the fourth quarter. Handelsbanken Fonder AB now owns 31,633 shares of the biopharmaceutical company's stock worth $990,000 after purchasing an additional 700 shares during the last quarter. Swiss National Bank grew its stake in shares of ACADIA Pharmaceuticals by 0.4% in the first quarter. Swiss National Bank now owns 210,604 shares of the biopharmaceutical company's stock worth $3,894,000 after purchasing an additional 800 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of ACADIA Pharmaceuticals by 1.6% in the fourth quarter. Franklin Resources Inc. now owns 50,405 shares of the biopharmaceutical company's stock worth $1,578,000 after purchasing an additional 803 shares during the last quarter. Finally, Covestor Ltd grew its stake in shares of ACADIA Pharmaceuticals by 70.5% in the first quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 840 shares during the last quarter. Institutional investors own 96.71% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近调整了他们对该股票的持股。Empire Life Investments Inc. 在第四季度增加了对 ACADIA Pharmaceuticals 股份的持股比例，增长了 0.3%。Empire Life Investments Inc. 现在拥有 174,815 股这家生物制药公司的股票，价值$5,473,000，上季度购买了额外的 467 股。Handelsbanken Fonder AB 在第四季度增加了对 ACADIA Pharmaceuticals 股份的持股比例，增长了 2.3%。Handelsbanken Fonder AB 现在拥有 31,633 股这家生物制药公司的股票，价值$990,000，上季度购买了额外的 700 股。瑞士国家银行在第一季度增加了对 ACADIA Pharmaceuticals 股份的持股比例，增长了 0.4%。瑞士国家银行现在拥有 210,604 股这家生物制药公司的股票，价值$3,894,000，上季度购买了额外的 800 股。Franklin Resources Inc. 在第四季度增加了对 ACADIA Pharmaceuticals 股份的持股比例，增长了 1.6%。Franklin Resources Inc. 现在拥有 50,405 股这家生物制药公司的股票，价值$1,578,000，上季度购买了额外的 803 股。最后，Covestor Ltd 在第一季度增加了对 ACADIA Pharmaceuticals 股份的持股比例，增长了 70.5%。Covestor Ltd 现在拥有 2,032 股这家生物制药公司的股票，价值$38,000，上季度购买了额外的 840 股。机构投资者持有该公司股份的 96.71%。</p>
</div><h2>About ACADIA Pharmaceuticals (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 ACADIA Pharmaceuticals（获取免费报告）</h2>
</div><p>ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.</p>
<div class="lb-trans"><p>ACADIA Pharmaceuticals Inc. 是一家生物制药公司，专注于开发和商业化解决美国中枢神经系统（CNS）疾病和罕见疾病未满足医疗需求的创新药物。该公司提供 NUPLAZID（pimavanserin）用于治疗帕金森病精神病的幻觉和妄想；以及 DAYBUE，一种胰岛素样生长因子 1 氨基末端三肽的新型合成类似物，用于治疗雷特综合征。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than ACADIA Pharmaceuticals</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>Top 3 Beverage Stocks: Summer Earnings Reveal Key Trends</li>
<li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness</li>
<li>This Financial Stock's Earnings Signal a Buying Opportunity</li>
<li>What Are Trending Stocks? Trending Stocks Explained</li>
<li>Social Platform Stock Hits New Highs: Is More Growth Ahead?</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>五只我们比 ACADIA Pharmaceuticals 更喜欢的股票</li>
<li>现在购买的 3 家最佳金融科技股</li>
<li>前三家饮料股：夏季收益揭示关键趋势</li>
<li>股息王子宝洁在盈利下滑后值得购买</li>
<li>这家金融股的盈利信号表明购买机会</li>
<li>什么是热门股票？热门股票解析</li>
<li>社交平台股价创新高：未来还有更多增长吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNBRA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ACAD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和来自市场预测的金融数据生成的，以便为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Obama’s DNC coup (From Stansberry Research)(Ad)</p>
<div class="lb-trans"><p>→ 奥巴马的民主党全国委员会政变（来自 Stansberry Research）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjQ2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8646&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in ACADIA Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资$1,000 在 ACADIA Pharmaceuticals？</h2>
</div><p>Before you consider ACADIA Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 ACADIA Pharmaceuticals 之前，您会想听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户在更广泛市场注意之前现在购买的股票... 而 ACADIA Pharmaceuticals 不在这个名单上。</p>
</div><p>While ACADIA Pharmaceuticals currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 ACADIA Pharmaceuticals 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

阿卡迪亚制药（NASDAQ:ACAD）的目标价被下调至 28.00 美元